Literature DB >> 10406192

Purification of antigenic peptide from murine hepatoma cells recognized by Class-I major histocompatibility complex molecule-restricted cytotoxic T-lymphocytes induced with B7-1-gene-transfected hepatoma cells.

K Nakatsuka1, H Sugiyama, Y Nakagawa, H Takahashi.   

Abstract

BACKGROUND/AIM: It has been reported that expression of costimulatory molecules, such as B7, on tumors is essential for priming tumor-specific cytotoxic T-lymphocytes (CTLs). Here, we have attempted to induce murine hepatoma-specific CTLs by immunizing with the B7-1-gene-expressing hepatoma cells, and to identify the epitope(s) presented on the hepatoma cells.
METHODS: The B7-1-gene encoding plasmid was transferred into the murine hepatoma cell line, Hepa1-6. Syngeneic C57BL/6 mice were immunized with the B7-1-transfected cells via various routes to prime CTLs. The mild acid elution method was used to isolate antigenic fractions from the class-I major histocompatibility complex (MHC) molecules on the Hepa1-6 cells. Cytotoxicity was measured by standard 51Cr-releasing assay. The effect of the CTLs on hepatoma growth was evaluated in hepatoma-bearing SCID mice to which the cells were preadministered.
RESULTS: A clone, termed L1, highly expressing the B7-1-gene, has been established. Killer cells generated from mice immunized intraperitoneally with L1 cells eliminated both L1 and Hepa1-6 cells, and also another syngeneic hepatoma cell line, Hepa1-clc7. The killer cells were CD8+ and the class-I MHC molecule-restricted CTLs which might recognize hepatoma-specific antigenic peptide(s) in association with the D(b)class-I MHC molecules. A functional peptide fraction was obtained from eluted fluid of the Hepa1-6 cells. In addition, intravenous preadministration of the CTLs inhibited the hepatoma growth in SCID mice.
CONCLUSIONS: The hepatoma epitope-specific CTLs which suppressed hepatoma growth in vivo could be generated with the B7-1-gene-transfected hepatoma cells. These results will be useful in establishing immunotherapy against hepatocellular carcinoma.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10406192     DOI: 10.1016/s0168-8278(99)80268-2

Source DB:  PubMed          Journal:  J Hepatol        ISSN: 0168-8278            Impact factor:   25.083


  6 in total

1.  Induction of tumor-specific acquired immunity against already established tumors by selective stimulation of innate DEC-205(+) dendritic cells.

Authors:  Keiichi Moriya; Ayako Wakabayashi; Masumi Shimizu; Hideto Tamura; Kazuo Dan; Hidemi Takahashi
Journal:  Cancer Immunol Immunother       Date:  2010-03-10       Impact factor: 6.968

2.  Identification of two new HLA-A*0201-restricted cytotoxic T lymphocyte epitopes from colorectal carcinoma-associated antigen PLAC1/CP1.

Authors:  Fangfang Liu; Henghui Zhang; Danhua Shen; Shan Wang; Yingjiang Ye; Hongsong Chen; Xuewen Pang; Qiujing Song; Peiying He
Journal:  J Gastroenterol       Date:  2013-04-21       Impact factor: 7.527

3.  Synergetic anticancer effect of combined quercetin and recombinant adenoviral vector expressing human wild-type p53, GM-CSF and B7-1 genes on hepatocellular carcinoma cells in vitro.

Authors:  Ming Shi; Fu-Sheng Wang; Zu-Ze Wu
Journal:  World J Gastroenterol       Date:  2003-01       Impact factor: 5.742

4.  Inactivation of tumor-specific CD8⁺ CTLs by tumor-infiltrating tolerogenic dendritic cells.

Authors:  Hirotomo Harimoto; Masumi Shimizu; Yohko Nakagawa; Katsuhisa Nakatsuka; Ayako Wakabayashi; Choitsu Sakamoto; Hidemi Takahashi
Journal:  Immunol Cell Biol       Date:  2013-09-10       Impact factor: 5.126

5.  Suppression of murine tumour growth through CD8+ cytotoxic T lymphocytes via activated DEC-205+ dendritic cells by sequential administration of α-galactosylceramide in vivo.

Authors:  Hideki Kogo; Masumi Shimizu; Yasuyuki Negishi; Eiji Uchida; Hidemi Takahashi
Journal:  Immunology       Date:  2017-04-18       Impact factor: 7.397

6.  Design and development of a robotized system coupled to µCT imaging for intratumoral drug evaluation in a HCC mouse model.

Authors:  Gaétan Bour; Fernand Martel; Laurent Goffin; Bernard Bayle; Jacques Gangloff; Marc Aprahamian; Jacques Marescaux; Jean-Marc Egly
Journal:  PLoS One       Date:  2014-09-09       Impact factor: 3.240

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.